Agentix Corp.

Agentix Corp. is a clinical development stage corporation focused on pharmaceutical treatments in the metabolic disease space. The company was incorporated in Nevada on April 18, 2013, and its fiscal year ends on March 31. Effective June 17, 2019, the company changed its name from FairWind Energy, Inc. to Agentix Corp. to reflect its new business focus. Until recently, Agentix Corp.'s business plan involved the design, engineering, and manufacturing of composite products, specifically supplying products to the oil and gas industry. However, on May 28, 2020, the company entered into a Share Exchange Agreement with GSL Healthcare, Inc., a Nevada corporation, and its two common stockholders. The closing occurred on June 1, 2020. Under this agreement, Agentix Corp. issued 27,932,271 shares of its common stock in exchange for all outstanding common stock of GSL Healthcare. As a result, the two former GSL Healthcare shareholders now own approximately 88.0% of Agentix Corp.'s issued common stock, and GSL Healthcare is a wholly-owned subsidiary. Following the Share Exchange Agreement, Agentix Corp. plans to focus its business efforts on developing and commercializing novel therapeutics to treat metabolic disease. Its primary objective is to develop two key assets specifically designed not to cross the blood-brain barrier, meaning they are "peripherally-restricted." In September 2022, the company established Agentix Australia Pty Ltd, a subsidiary in Australia, to conduct development activities for these two key assets. This subsidiary is operational and participates in a tax rebate program that reimburses 43.5% of expenses for biotechnology and/or pharmaceutical development activities conducted in Australia. Agentix Corp. has not yet generated or realized meaningful revenues from its current business.